You are here: Industry Insights > Novartis

News List

Novartis’ CAR-T therapy Kymriah hits endpoint in follicular lymphoma trial pharmatimes
August 05, 2020
Novartis has revealed positive results from a phase 2 study of its CAR-T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory follicular lymphoma.
Cosentyx wins EU approval for first-line paediatric psoriasis pharmatimes
August 04, 2020
Novartis’ Cosentyx (secukinumab) has been granted approval by the European Commission as a treatment for moderate-to-severe plaque psoriasis in children and adolescents aged six to <18 years.
Sandoz Announces Joint Investment with Austrian Government contractpharma
August 04, 2020
Aims to drive long-term competitiveness of European production for key antibiotics in Europe.
Novartis partners with Sangamo on genomic therapies pharmaceutical-technology
August 03, 2020
Novartis has signed an exclusive, global licensing collaboration agreement with Sangamo Therapeutics to develop and commercialise genomic therapies for neurodevelopmental disorders, including autism.
EU regulators approve Novartis' breast cancer combo pharmatimes
July 31, 2020
European regulators have approved Novartis' Piqray (alpelisib) in combination with fulvestrant for the treatment of a certain type of breast cancer.
Sangamo, Novartis Partner to Develop Gene Therapies for Autism contractpharma
July 31, 2020
Sangamo will receive $75M upfront and is eligible to receive up to $720M in potential milestones for three neurodevelopmental targets.
Novartis Launches Not-for-Profit Portfolio for Symptomatic Treatment of COVID-19 americanpharmaceuticalreview
July 24, 2020
Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a critical need in the absence of a vaccine or curative treatment.
Docquity partners with global pharma leader to support the continuing education of medical professionals across 7 countries in Asia prnasia
July 20, 2020
Docquity, Southeast Asia's largest professional network of doctors, has partnered with Swiss research-based healthcare company Novartis to deliver bite-sized, continual learning, and education support to doctors across seven countries in Asia.
Novartis launches not-for-profit COVID-19 medications portfolio europeanpharmaceuticalreview
July 20, 2020
The portfolio will be offered to low- and lower-middle-income countries to help financially strained healthcare systems care for COVID-19 patients.
Novartis offers non-profit medicines portfolio for Covid-19 pharmaceutical-technology
July 17, 2020
Swiss pharmaceutical giant Novartis has launched a not-for-profit medicines portfolio to help treat Covid-19 symptoms in patients in low-income and lower-middle-income countries.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page